During the research license period, Crucell and LFB Biotechnologies also will evaluate a joint collaboration to enhance sugar
structures, described as glycosylation patterns, on recombinant antibodies using LFB's proprietary technology. Crucell's and
DSM's technology platform was developed for the large-scale manufacture of biopharmaceutical products, including vaccines.
DRAXIS Names President
DRAXIS Health Inc. (Mississauga, ON, Canada) appointed Jean-Pierre Robert as president of DRAXIS Specialty Pharmaceuticals Inc. (DSP), the
company's wholly owned operating subsidiary that providers sterile, nonsterile, and radiopharmaceutical products. Robert will
have responsibility for DRAXIS Pharma, the contract manufacturing division of DSP, which serves clients in the pharmaceutical
and biotechnology sectors.